{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:57:12Z","timestamp":1789750632035,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:00:00Z","timestamp":1479254400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s10067-016-3480-x","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T06:45:41Z","timestamp":1479365141000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study"],"prefix":"10.1007","volume":"36","author":[{"given":"Claudia","family":"Fabiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Vannozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bacherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"3480_CR1","first-page":"S112","volume":"32","author":"G Hatemi","year":"2014","unstructured":"Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2014) Beh\u00e7et\u2019s syndrome: a critical digest of the 2013-2014 literature. Clin Exp Rheumatol 32:S112\u2013S122","journal-title":"Clin Exp Rheumatol"},{"key":"3480_CR2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","volume":"91","author":"N Kitaichi","year":"2007","unstructured":"Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Beh\u00e7et\u2019s disease: an international collaborative study. Br J Ophthalmol 91:1579\u20131582. doi: 10.1136\/bjo.2007.123554","journal-title":"Br J Ophthalmol"},{"key":"3480_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol 138:373\u2013380. doi: 10.1016\/j.ajo.2004.03.022","journal-title":"Am J Ophthalmol"},{"key":"3480_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60\u201376","journal-title":"Medicine (Baltimore)"},{"key":"3480_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/09273948.2011.649153","volume":"20","author":"D Wakefield","year":"2012","unstructured":"Wakefield D, Cunningham ET Jr, Tugal-Tutkun I, Khairallah M, Ohno S, Zierhut M (2012) Controversies in Beh\u00e7et disease. Ocul Immunol Inflamm 20:6\u201311. doi: 10.3109\/09273948.2011.649153","journal-title":"Ocul Immunol Inflamm"},{"key":"3480_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P et al (2007) Epidemiology and clinical course of Beh\u00e7et\u2019s disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheumn 57:171\u2013178. doi: 10.1002\/art.22500","journal-title":"Arthritis Rheumn"},{"key":"3480_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10067-015-2906-1","volume":"35","author":"R Talarico","year":"2016","unstructured":"Talarico R, Cantarini L, d\u2019Ascanio A, Figus M, Favati B, Baldini C et al (2016) Development of de novo major involvement during follow-up in Beh\u00e7et\u2019s syndrome. Clin Rheumatol 35:247\u2013250. doi: 10.1007\/s10067-015-2906-1","journal-title":"Clin Rheumatol"},{"key":"3480_CR8","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2008) EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67:1656\u20131662. doi: 10.1136\/ard.2007.080432","journal-title":"Ann Rheum Dis"},{"key":"3480_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-9-16","volume":"9","author":"RJ Barry","year":"2014","unstructured":"Barry RJ, Markandey B, Malhotra R, Knott H, Joji N, Mubin M et al (2014) Evidence-based practice in Beh\u00e7et\u2019s disease: identifying areas of unmet need for 2014. Orphanet J Rare Dis 9:16. doi: 10.1186\/1750-1172-9-16","journal-title":"Orphanet J Rare Dis"},{"key":"3480_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/BOR.0000000000000231","volume":"28","author":"Y Ozguler","year":"2016","unstructured":"Ozguler Y, Hatemi G (2016) Management of Beh\u00e7et\u2019s syndrome. Curr Opin Rheumatol 28:45\u201350. doi: 10.1097\/BOR.0000000000000231","journal-title":"Curr Opin Rheumatol"},{"key":"3480_CR11","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s10067-016-3318-6","volume":"35","author":"H Kavandi","year":"2016","unstructured":"Kavandi H, Khabbazi A, Kolahi S, Hajialilo M, Shayan FK, Oliaei M (2016) Long-term efficacy and safety of interferon \u03b1-2a therapy in severe refractory ophthalmic Behcet\u2019s disease. Clin Rheumatol 35:2765\u20132769. doi: 10.1007\/s10067-016-3318-6","journal-title":"Clin Rheumatol"},{"key":"3480_CR12","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s10067-016-3426-3","volume":"35","author":"C Fabiani","year":"2016","unstructured":"Fabiani C, Vitale A, Lopalco G, Iannone F, Frediani B, Cantarini L (2016) Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol 35:2631\u20132638. doi: 10.1007\/s10067-016-3426-3","journal-title":"Clin Rheumatol"},{"key":"3480_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","volume":"60","author":"M Cordero-Coma","year":"2015","unstructured":"Cordero-Coma M, Sobrin L (2015) Anti-tumor necrosis factor-\u03b1 therapy in uveitis. Surv Ophthalmol 60:575\u2013589. doi: 10.1016\/j.survophthal.2015.06.004","journal-title":"Surv Ophthalmol"},{"key":"3480_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785\u201396.e3. doi: 10.1016\/j.ophtha.2013.09.048","journal-title":"Ophthalmology"},{"key":"3480_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/ICU.0000000000000210","volume":"26","author":"C Fabiani","year":"2015","unstructured":"Fabiani C, Ali\u00f3 JL (2015) Local (topical and intraocular) therapy for ocular Adamantiades-Beh\u00e7et\u2019s disease. Curr Opin Ophthalmol 26:546\u2013552. doi: 10.1097\/ICU.0000000000000210","journal-title":"Curr Opin Ophthalmol"},{"key":"3480_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61\u201370. doi: 10.1016\/j.semarthrit.2010.09.002","journal-title":"Semin Arthritis Rheum"},{"key":"3480_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Beh\u00e7et\u2019s Disease Research Group Of Japan (2012) Ocular Beh\u00e7et\u2019s disease research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 130:592\u2013598. doi: 10.1001\/archophthalmol.2011.2698","journal-title":"Arch Ophthalmol"},{"key":"3480_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/bjo.2009.174888","volume":"95","author":"S Sugita","year":"2011","unstructured":"Sugita S, Yamada Y, Mochizuki M (2011) Relationship between serum infliximab levels and acute uveitis attacks in patients with Beh\u00e7et disease. Br J Ophthalmol 95:549\u2013552. doi: 10.1136\/bjo.2009.174888","journal-title":"Br J Ophthalmol"},{"key":"3480_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bjo.2010.194464","volume":"95","author":"H Keino","year":"2011","unstructured":"Keino H, Okada AA, Watanabe T, Taki W (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh\u00e7et\u2019s disease on infliximab therapy. Br J Ophthalmol 95:1245\u20131250. doi: 10.1136\/bjo.2010.194464","journal-title":"Br J Ophthalmol"},{"key":"3480_CR20","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum 52:2478\u20132484. doi: 10.1002\/art.21231","journal-title":"Arthritis Rheum"},{"key":"3480_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassar\u00e0 E, Salvarani C et al (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et\u2019s disease: a 24-month follow-up study. Rheumatology (Oxford) 46:1161\u20131164. doi: 10.1093\/rheumatology\/kem101","journal-title":"Rheumatology (Oxford)"},{"key":"3480_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","volume":"21","author":"S Al Rashidi","year":"2013","unstructured":"Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM (2013) Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab. Ocul Immunol Inflamm 21:468\u2013474. doi: 10.3109\/09273948.2013.779727","journal-title":"Ocul Immunol Inflamm"},{"key":"3480_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-de-Vicu\u00f1a C, Cordero-Coma M, Ortega G, Ortego N et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575\u20131581. doi: 10.1016\/j.ophtha.2012.02.018","journal-title":"Ophthalmology"},{"key":"3480_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/09273948.2010.483314","volume":"18","author":"A Bawazeer","year":"2010","unstructured":"Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Beh\u00e7et disease. Ocul Immunol Inflamm 18:226\u2013232. doi: 10.3109\/09273948.2010.483314","journal-title":"Ocul Immunol Inflamm"},{"key":"3480_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"K Takase","year":"2011","unstructured":"Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis. Rheumatol Int 31:243\u2013245. doi: 10.1007\/s00296-009-1178-y","journal-title":"Rheumatol Int"},{"key":"3480_CR26","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Beh\u00e7et\u2019s disease. Eye (Lond) 21:824\u2013825. doi: 10.1038\/sj.eye.6702352","journal-title":"Eye (Lond)"},{"key":"3480_CR27","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","volume":"51","author":"D Perra","year":"2012","unstructured":"Perra D, Alba MA, Callejas JL, Mesquida M, R\u00edos-Fern\u00e1ndez R, Ad\u00e1n A et al (2012) Adalimumab for the treatment of Beh\u00e7et\u2019s disease: experience in 19 patients. Rheumatology (Oxford) 51:1825\u20131831. doi: 10.1093\/rheumatology\/kes130","journal-title":"Rheumatology (Oxford)"},{"key":"3480_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.reuma.2010.10.003","volume":"7","author":"J Calvo Catal\u00e1","year":"2011","unstructured":"Calvo Catal\u00e1 J, Campos Fern\u00e1ndez C, Rueda Cid A, Gonz\u00e1lez-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD (2011) Efficacy of adalimumab in Beh\u00e7et\u2019s disease. Description of 6 cases. Reumatol Clin 7:258\u2013261. doi: 10.1016\/j.reuma.2010.10.003","journal-title":"Reumatol Clin"},{"key":"3480_CR29","first-page":"S58","volume":"32","author":"E Interlandi","year":"2014","unstructured":"Interlandi E, Leccese P, Olivieri I, Latanza L (2014) Adalimumab for treatment of severe Beh\u00e7et\u2019s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol 32:S58\u2013S62","journal-title":"Clin Exp Rheumatol"},{"key":"3480_CR30","first-page":"S93","volume":"29","author":"P Leccese","year":"2011","unstructured":"Leccese P, Latanza L, D\u2019Angelo S, Padula A, Olivieri I (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Beh\u00e7et\u2019s disease to infliximab. Clin Exp Rheumatol 29:S93","journal-title":"Clin Exp Rheumatol"},{"key":"3480_CR31","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A et al (2014) Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53:2223\u20132231. doi: 10.1093\/rheumatology\/keu266","journal-title":"Rheumatology (Oxford)"},{"key":"3480_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O et al (2015) Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun 62:67\u201374. doi: 10.1016\/j.jaut.2015.06.005","journal-title":"J Autoimmun"},{"key":"3480_CR33","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","unstructured":"Criteria for diagnosis of Beh\u00e7et\u2019s disease (1990) International study group for Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"3480_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD) (2014) The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338\u2013347. doi: 10.1111\/jdv.12107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3480_CR35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10067-006-0484-y","volume":"26","author":"FS Neves","year":"2007","unstructured":"Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gon\u00e7alves CR (2007) Cross-cultural adaptation of the Beh\u00e7et\u2019s disease current activity form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 26:1263\u20131267. doi: 10.1007\/s10067-006-0484-y","journal-title":"Clin Rheumatol"},{"key":"3480_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/BTT.S27343","volume":"6","author":"F Cantini","year":"2012","unstructured":"Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassar\u00e0 E, Susini M et al (2012) Efficacy of infliximab in refractory Beh\u00e7et\u2019s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 6:5\u20131. doi: 10.2147\/BTT.S27343","journal-title":"Biologics"},{"key":"3480_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00417-013-2552-8","volume":"252","author":"M Schaap-Fogler","year":"2014","unstructured":"Schaap-Fogler M, Amer R, Friling R, Priel E, Kramer M (2014) Anti-TNF-\u03b1 agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol 252:633\u2013640. doi: 10.1007\/s00417-013-2552-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3480_CR38","first-page":"S54","volume":"29","author":"I Olivieri","year":"2011","unstructured":"Olivieri I, Leccese P, D\u2019Angelo S, Padula A, Nigro A, Palazzi C et al (2011) Efficacy of adalimumab in patients with Beh\u00e7et\u2019s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29:S54\u2013S57","journal-title":"Clin Exp Rheumatol"},{"key":"3480_CR39","first-page":"S79","volume":"30","author":"H Yazici","year":"2012","unstructured":"Yazici H, Hatemi G (2012) Empiricism in managing Beh\u00e7et\u2019s syndrome. Clin Exp Rheumatol 30:S79","journal-title":"Clin Exp Rheumatol"},{"key":"3480_CR40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"3480_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/09273940903348835","volume":"18","author":"M Khairallah","year":"2010","unstructured":"Khairallah M (2010) Are the Standardization of the Uveitis Nomenclature (SUN) Working Group criteria for codifying the site of inflammation appropriate for all uveitis problems? Limitations of the SUN Working Group classification. Ocul Immunol Inflamm 18:2\u20134. doi: 10.3109\/09273940903348835","journal-title":"Ocul Immunol Inflamm"},{"key":"3480_CR42","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3899\/jrheum.131249","volume":"41","author":"G Hatemi","year":"2014","unstructured":"Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ et al (2014) Outcome measures used in clinical trials for Beh\u00e7et syndrome: a systematic review. J Rheumatol 41:599\u2013612. doi: 10.3899\/jrheum.131249","journal-title":"J Rheumatol"},{"key":"3480_CR43","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.3899\/jrheum.141147","volume":"42","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Ozguler Y, Direskeneli H, Mahr A, Gul A, Levi V et al (2015) Current status, goals, and research agenda for outcome measures development in Beh\u00e7et syndrome: report from OMERACT 2014. J Rheumatol 42:2436\u20132441. doi: 10.3899\/jrheum.141147","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3480-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:48:12Z","timestamp":1498362492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3480-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3480"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3480-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,16]]}}}